Back to Journals » ImmunoTargets and Therapy » Volume 13
Original Research
Survival Benefit of Synchronous Lenvatinib Combined PD-1 Inhibitors for Advanced Hepatocellular Carcinoma Beyond Oligometastasis
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
441 | Dovepress* | 441+ | 10 | 451 | |
Totals | 441 | 10 | 451 | ||
*Since 17 June 2024 |
View citations on PubMed Central and Google Scholar